EpiCept Corporation shares up 28%
EPCT says that Myriad Genetics Inc has reported positive clinical results for Azixa, a compound discovered by EpiCept and licensed to Myriad. Based on the results, Myriad intends to initiate Phase II clinical trials, triggering a milestone payment to EpiCept.
EPCT says that Myriad Genetics Inc has reported positive clinical results for Azixa, a compound discovered by EpiCept and licensed to Myriad. Based on the results, Myriad intends to initiate Phase II clinical trials, triggering a milestone payment to EpiCept.
posted by doublezero at
8:26 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home